Urinary incontinence treating

In addition to treating MDD [51-53], duloxetine was approved as the first agent for the treatment of painful diabetic neuropathy in the U.S. [54-56]. It also has been used for stress urinary incontinence in women in Europe [57,58]. In 2007, duloxetine was approved for the treatment of generalized anxiety disorder in the U.S. 

Urinary incontinence can be caused and worsened by drug treatment for diverse chronic conditions and should be treated with a multifactor aim... 

Coriander Coriandrum sativum) Uses t Appetite, treat D, dyspep-sia, flatulence Action Stimulates gastric secretions, spasmolytic effects Available forms Tine 10-30 gtts PO OD Contra w/ PRG or lactation Notes/SE N/V, fatty liver tumors, allergic skin Rxns Interactions T Effects OF oral hypoglycemics EMS T Risk of photosensitivity Rxns may cause hypoglycemia Cranberry [Vaeeinium macreearpon) Uses Prevention UTI urinary deodorizer in urinary incontinence Actions Interferes w/ bacterial adherence to epithelial cells of the bladder Available forms Caps 300-500 mg PO bid-qid unsweetened juice 8-16 oz daily tine 3-5 mL or tincture 1/2-1 tsp up to 3X/d, tea 2-3 tsps of dried flowers/cup creams apply topically 2-3X/d PO SE D, irritation, nephrolithiasis if T urinary Ca oxalate Interactions T Effects OF warfarin ... 

Some of the growth in antidepressant use may be related to the broad application of these agents for conditions other than major depression. For example, antidepressants have received FDA approvals for the treatment of panic disorder, generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD), and obsessive-compulsive disorder (OCD). In addition, antidepressants are commonly used to treat pain disorders such as neuropathic pain and the pain associated with fibromyalgia. Some antidepressants are used for treating premenstrual dysphoric disorder (PMDD), mitigating the vasomotor symptoms of menopause, and treating stress urinary incontinence. Thus, antidepressants have a broad... 

Agrimony is believed to possess mild astringent and diuretic properties. It is used to treat diarrhea in children, mucous colitis, grumbling appendicitis, urinary incontinence, cystitis, and as a gargle for acute sore throat and chronic nasopharyngeal catarrh. 

Urinary incontinence, or leakage, that may be associated with diuretic use can cause social embarrassment, self-esteem issues, depression, and anxiety. A person suffering from incontinence may stop participating in social activities, sports, and other activities they once enjoyed because of the risk of embarrassing accidents. Bladder training, biofeedback, pelvic toning exercises, or special urethral or vaginal inserts may help to treat urinary incontinence problems related to diuretics. 

Title Compounds and Methods for Treating Urinary Incontinence F. Esser et al, US Patent 7,019,021 (March 28, 2006)... 

A 61-year-old man with bipolar disorder treated with olanzapine and lithium developed urinary incontinence 4 days later (235). He was successfully treated with ephedrine 25 mg/day. 

Urinary incontinence in patients with Down syndrome treated with donepezil has been described before (67). Urinary incontinence can be a major concern and a source of distress, not only for patients but also for caregivers. Clinicians should be alert to the possibility of urinary incontinence when prescribing donepezil for individuals with Alzheimer s disease. The authors emphasized that the incontinence may often be transient and not serious, but it could limit a patient s activities and quality of life and could also affect therapeutic adherence. 

Three patients with Alzheimer s disease associated with Down syndrome were treated with donepezil (67). One became agitated and aggressive the other two developed urinary incontinence. In all three cases donepezil was withdrawn. These results are important, because many individuals with Down syndrome... 

As noted previously, anticholinergic agents have undergone something of a renaissance due to their use as drugs to treat urinary incontinence. The synthesis of one of these muscarinic antagonsists starts with the classic... 

Refluxing ureters can be treated endoscopically with sub-ureteric injection of polytetrafluoroethylene paste (Polytef), the STING procedure. However, ureteric obstruction has been described as a complication (8). Urinary incontinence has also been treated by periurethral or submucosal injections of Polytef, but reports of urinary obstruction (9,10) and poor long-term success (11,12) have limited the range of indications for this treatment. Other reported complications of Teflon injection for stress urinary incontinence include periurethral abscess, urethral diverticulum. Teflon granuloma with urethral wall prolapse (13), and microembolization (14). 

This can be based on the incidence of disease proportional to gender distribution and can be studied when drug development and toxicity are well-enough advanced, usually by phase III. Women of childbearing age must be represented if the disease is prevalent in the age group of 15-50 years. Indeed, diseases such as endometriosis can only be studied in such a population, whereas drugs to treat urinary incontinence would be better undertaken in older patients. 

Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003 62 237-242. 

Trospium is a quaternary amine long used in Europe and approved recently for use in the United States for treatment of overactive bladder. It has been shown to be as effective as oxybutynin with better tolerability. Solifenacin is newly approved for overactive bladder with a favorable efficacy side effect ratio. Stress urinary incontinence has been treated with some success with duloxetine (Yentreve), which acts centrally to influence serotonin and norepinephrine levels. 

---